logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Jonathan Daniel Heller

This inventor holds 14 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Johns Hopkins University, Erimos Pharmaceuticals, LLC, Predicant Biosciences, Inc.. Active years: 2001-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Daniel Heller. Retrieved from https://idiyas.com/inventor/jonathan-daniel-heller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 

% Patents Active = 85.7



Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 112(Granted Patents)


Location History:

  • Dundalk, MD (US) (2001 - 2012)
  • Raleigh, NC (US) (2010 - 2013)
  • San Francisco, CA (US) (2006 - 2015)
  • San Francisco, FL (US) (2014 - 2016)

Company Filing History:

goldMedal8 out of 3,801 
 
Johns Hopkins University
 patents
silverMedal7 out of 8 
 
Erimos Pharmaceuticals, LLC
 patents
bronzeMedal1 out of 5 
 
Predicant Biosciences, Inc.
 patents
4. 1 out of 2,027 
 
University System of Maryland
 patents
where one patent can have more than one assignee

Years Active: 2001-2016

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 9481660 - [object Object] (2016-11-01),
2. 9067875 - Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use (2015-06-30),
3. 8691845 - Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use (2014-04-08),
4. 8440648 - Methods and compositions for treatment of intraepithelial neoplasia (2013-05-14),
5. 8318815 - Method for treatment of tumors using nordihydroguaiaretic acid derivatives (2012-11-27),
6. 8232277 - Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use (2012-07-31),
7. 8178527 - Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use (2012-05-15),
8. 7728036 - Methods for delivery of catecholic butanes for treatment of tumors (2010-06-01),
9. 7007710 - Microfluidic devices and methods (2006-03-07),
10. 6958411 - Nordihydroguaiartic derivatives for use in treatment of tumors (2005-10-25),
11. 6777444 - Method for regulation of gene expression in eukaryotic cells using nordihydroguaiaretic acid derivatives (2004-08-17),
12. 6608108 - Method for treatment of tumors using nordihydroguaiaretic acid derivatives (2003-08-19),
13. 6417234 - Nordihydroguaiaretic derivatives for use in treatment of tumors (2002-07-09),
14. 6214874 - Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N (2001-04-10),

Title: Innovations of Jonathan Daniel Heller

Introduction

Jonathan Daniel Heller is a prominent inventor based in San Francisco, CA. He holds a total of 14 patents, showcasing his significant contributions to the field of pharmaceutical sciences. His work primarily focuses on developing novel compounds for treating various diseases.

Latest Patents

Heller's latest patents include innovative nordihydroguaiaretic acid derivative compounds. These compounds are designed for pharmaceutical compositions aimed at treating diseases associated with viral infections, inflammatory diseases, metabolic diseases, and proliferative diseases such as cancer. His research also encompasses tetra-substituted NDGA derivatives, which are synthesized through ether and carbamate bonds, further expanding the potential applications of these compounds in medical treatments.

Career Highlights

Throughout his career, Heller has worked with esteemed institutions such as The Johns Hopkins University and Erimos Pharmaceuticals, LLC. His experience in these organizations has allowed him to advance his research and contribute to significant medical advancements.

Collaborations

Heller has collaborated with notable colleagues, including Ru Chih C Huang and Rocio Alejandra Lopez. These partnerships have facilitated the exchange of ideas and expertise, enhancing the impact of his work.

Conclusion

Jonathan Daniel Heller's innovative contributions to pharmaceutical sciences through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…